AngioGenex (AGGX)

Company Profile

AngioGenex, Inc. operates as a biopharmaceutical company, which engages in developing and commercializing novel platform of anti-proliferative drugs for the treatment of cancer and macular degeneration. The company was founded by Michael M. Strage and Robert Benezra on March 31, 1999 and is headquartered in New York, NY.

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Nov 21	Michael Aronstein	Convertible Note Common Stock	Grant	Acquire A	No	No	25	240,000	6.00 mm	5,240,000
2 Sep 21	Michael Aronstein	Stock Option Common Stock	Grant	Acquire A	No	No	0	2,000,000	0.00	5,000,000
2 Sep 21	Dickey Robert IV	Stock Option Common Stock	Grant	Acquire A	No	No	0.13	250,000	32.50 k	850,000
2 Sep 21	Michael M Strage	Stock Option Common Stock	Grant	Acquire A	No	No	0.13	250,000	32.50 k	1,333,333
2 Sep 21	Martin Murray	Stock Option Common Stock	Grant	Acquire A	No	No	0.13	50,000	6.50 k	125,000
31 Aug 21	Michael Aronstein	Common Stock	Grant	Acquire A	No	No	0.13333333333333333	750,000	100.00 k	7,507,827
6 Jul 21	Michael M Strage	Common Stock	Grant	Acquire A	No	No	0.05555555555555555	270,000	15.00 k	6,043,014
8 Jun 21	Michael Aronstein	Common Stock	Grant	Acquire A	No	No	0.1100003520011264	227,272	25.00 k	7,507,827
2 Mar 21	Michael Aronstein	Common Stock	Grant	Acquire A	No	No	0.25	400,000	100.00 k	7,507,827
8 Oct 20	Michael Aronstein	Common Stock	Grant	Acquire A	No	No	10000	55,555	555.55 mm	6,130,555

AngioGenex (AGGX)

Company profile

AGGX stock data

Recent insider trades